13F Holdings
中文EN

VASO VASO Corp

Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 839087 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-1.2%
TTM net income YoY-5.0%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-5.9%
Net income 3-yr CAGR-40.6%

Margins

Gross margin68.2%
Operating margin-3.7%
Net margin3.6%
FCF margin—
EBITDA margin-2.3%

Returns

ROE8.3%
ROA2.9%
ROIC (approx.)—
Asset turnover0.82x

Leverage & solvency

Liabilities / assets62.8%
Debt / equity0.00x
Current ratio2.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.77x
Accruals ratio-5.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$89.10M$86.77M$81.02M$79.29M$75.58M
Cost of revenue$34.42M$34.72M$30.43M$31.39M$32.45M
Gross profit$54.67M$52.05M$50.59M$47.90M$43.13M
R&D expense$728,000$851,000$755,000$605,000$1.72M
SG&A expense$52.20M$48.98M$45.08M$40.84M$38.59M
Operating income-$2.89M$285,000$4.20M$6.45M$2.82M
Interest expense$25,000$4,000$50,000$44,000$312,000
Pretax income-$1.31M$1.28M$4.91M$6.55M$6.25M
Income tax-$2.88M$326,000$100,000-$4.74M$151,000
Net income$1.57M$951,000$4.80M$11.29M$6.10M
EBITDA-$2.03M$1.11M$5.19M$8.38M$6.66M
EPS (basic)0.010.010.030.070.04
EPS (diluted)0.010.010.030.06—
Weighted avg. shares (diluted)176.00M175.59M175.54M174.66M173.77M
Balance sheet
Cash & equivalents$34.08M$26.27M$11.34M$11.82M$6.03M
Short-term investments——$13.98M$8.50M$629,000
Receivables—$916,000$901,000$21.46M$21.20M
Inventory$833,000$911,000$1.47M$1.47M$1.15M
Current assets$58.56M$51.19M$45.10M$40.99M$27.80M
PP&E, net$121,000$1.54M$1.17M$1.34M$2.17M
Goodwill$1.23M$1.18M$15.59M$15.61M$15.72M
Intangibles$1.25M$1.61M$1.41M$1.51M$2.04M
Total assets$89.32M$82.94M$75.76M$71.64M$52.36M
Current liabilities$36.85M$34.72M$30.04M$31.51M$31.00M
Short-term debt———$9,000$8,000
Long-term debt———$15,000$23,000
Total debt———$24,000$31,000
Total liabilities$59.89M$55.24M$48.91M$49.58M$41.05M
Shareholders' equity$29.43M$27.70M$26.84M$22.07M$11.08M
Net debt———-$11.80M-$5.99M
Shares outstanding175.95M175.70M175.32M175.13M175.13M
Cash flow statement
Operating cash flow$9.27M$3.28M$5.30M$14.42M$7.82M
Capital expenditure———$566,000$415,000
Free cash flow———$13.85M$7.40M
Investing cash flow-$725,000$11.73M-$5.66M-$8.42M-$260,000
Financing cash flow$248,000-$89,000-$134,000-$230,000-$8.33M
Depreciation & amortization$858,000$824,000$999,000$1.92M$3.84M
Stock-based compensation$33,000$54,000$48,000$35,000$31,000

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.